



PTO/SB/21 (05-03)  
Approved for use through 04/30/2003. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/007,448	
	Filing Date	11/07/2001	
	First Named Inventor	David Lewis	
	Art Unit	1632	
	Examiner Name	Karen Lacourcier	
Total Number of Pages in This Submission	2	Attorney Docket Number	Mirus.030.03

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mark K. Johnson, Mirus Corporation
Signature	
Date	09/25/2003

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as express mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Kirk Ekena		
Signature		Date	09/25/2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FROM :Mirus & Takara Mirus Bio

FAX NO. :6084412845

Sep. 25 2003 02:26PM P1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dave Lewis,  
Hans Herweijer, Jon Wolff,  
Aaron Loomis, James Hagstrom

Serial No.: 10/007,448

Filed: Nov 7, 2001

Group Art Unit: 1632

Examiner: Karen Lacourcier

RECEIVED  
CENTRAL FAX CENTER

SEP 26 2003

OFFICIAL

For: Inhibition Of Gene Expression By Delivery Of Small Interfering RNA To Post-Embryonic Animal Cells *In vivo*

AMENDMENT UNDER 37 C.F.R. '1.111

Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231


Dear Examiner:

This Amendment responds to the Office Action dated July 3, 2003 and a telephone interview with the examiner. The Office Action requested a restriction of the claims. However, in the telephone interview, the Examiner agreed that the claim should be rejoined. Therefore, Applicants select the rejoined claims.

The Office Action further included a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. An amendment to the specification as well as the requested paper and computer readable sequence listings were mailed Aug 1, 2003.

If there are any questions, please contact the undersigned.

Respectfully submitted,

  
Mark K. Johnson Reg. No. 35,909  
Mirus  
505 South Rosa Road  
Madison, WI 53719  
608-238-4400

I hereby certify that this correspondence is being  
facsimile transmitted to the USPTO 703.308.4242;  
Assistant Commissioner for Patents, Washington, DC  
20231 on September 25, 2003.

  
Kirk Ekena